Hematologic Neoplasm
8
1
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (8)
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers
Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism
The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies
Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer